AlphAIalphai — Financial news for AI agents
lbc.co.ukAUG 242 min read$LLY

New weight loss and diabetes pill available in UK pharmacies

Eli Lilly's weight loss and diabetes pill, Orforglipron (Foundayo), is now available in UK pharmacies, approved by the MHRA. It's the first GLP-1 pill for weight loss in Europe. The company is working with NHS on potential rollout. Dosage starts at 0.8mg, increasing monthly. Pharmacists warn about counterfeit versions.

Original reporting
lbc.co.uk
Published Aug 24, 2026, 1:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 2:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
New weight loss and diabetes pill available in UK pharmacies — source image
Source · lbc.co.uk
Decision brief

The 30-second read

$LLYBullishMed
01

Why it matters

The approval expands Eli Lilly's product portfolio beyond injectables, opening a new revenue stream.

02

Market read

New drug approval could modestly lift LLY stock and influence the obesity‑treatment market.

03

What to watch

Potential supply chain constraints and NHS reimbursement negotiations could delay uptake.

Relevance 8/10Novelty 8/10Timing: earlier this month

Background

The MHRA approved Foundayo, an oral GLP‑1 tablet, marking the first UK/Europe approval of such a drug.

Company-level read

Ticker impact

$LLYBullishMedium confidence
Context

Eli Lilly received MHRA approval for its oral GLP‑1 pill Foundayo, the first UK/Europe launch of the drug.

Expected impact

Modest upside as investors price in new market exposure.

Evidence & confidence

First regulatory approval in Europe for an oral GLP‑1, but limited immediate sales volume.

Market effects

Sector

Strengthens the broader obesity‑treatment and diabetes sector with an oral alternative.

Regional

UK patients gain access, may pressure NHS budgeting and competitor pricing.

Global

Signals potential rollout in other European markets, affecting global GLP‑1 competitors.

Counterpoint

What could challenge this read

Oral formulation may face adherence challenges and lower efficacy versus injectables.

Key entities

  • Company
    Eli Lilly

    US pharmaceutical company developing the oral GLP‑1 pill.

  • Regulator
    MHRA

    UK Medicines and Healthcare products Regulatory Agency.

Read at source← All news

Also covered by

3 outlets

Related articles

AUG 24
$LLYMed

New once-daily weight loss pill now available in pharmacies across UK

Eli Lilly's new weight loss and diabetes pill, orforglipron (Foundayo), is now available in UK pharmacies. It's the second GLP-1 pill for weight loss in the UK, after Wegovy. The MHRA authorized it earlier this month. Eli Lilly is working with the NHS on potential health service rollout. The pill is for patients with BMI 30+ or BMI 27-30 with weight-related conditions. Dosage starts at 0.8mg, increasing monthly. Pharmacists highlight its significance for patients avoiding injectables.

the-independent.com2 min
AUG 21
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Bristol-Myers Squibb (BMY) will invest $2.3B in a Houston plant, part of a $40B U.S. investment. Eli Lilly (LLY) won UK approval for its weight-loss drug, Foundayo. BMY's investment aims to boost domestic manufacturing, while LLY expands internationally. Both companies face challenges, including patent expirations for BMY and market competition for LLY. Hedge funds show mixed interest in both stocks.

insidermonkey.com3 min
AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min